Insider trading is often portrayed as the domain of high-powered executives, shadowy hedge funds, and multimillion-dollar schemes unfolding in dramatic fashion. The reality is far more ordinary. Many enforcement actions arise not from elaborate conspiracies, but from relatively mundane circumstances involving individuals who simply find themselves in possession of information they should not use.
A recent SEC administrative proceeding illustrates this point with clarity. In April 2026, the Commission brought an action against an individual in connection with trades in the stock of ImmunityBio, Inc. The person was not a corporate executive or investment professional. She worked with the company in a documentary and promotional capacity, a role that nonetheless provided access to internal developments. When the company received adverse news from the U.S. Food and Drug Administration regarding a delayed drug approval, information that had not yet been made public, the individual sold her shares before the announcement. When the news became public, the stock price declined significantly, and she avoided losses of approximately $157,000.
From a legal standpoint, this is a straightforward insider trading case. From a practical standpoint, however, it is a reminder that insider trading rarely looks like it does in movies.
At its core, insider trading is not defined by the size of the transaction or the sophistication of the actor. It turns on the misuse of material nonpublic information. Information is considered material if there is a substantial likelihood that a reasonable investor would view it as important in making an investment decision: that is, if it would significantly alter the “total mix” of information available in the market. Earnings results, regulatory decisions, mergers and acquisitions, significant contracts, or major operational developments all routinely qualify. Information is nonpublic if it has not been disseminated broadly to the investing public in a manner that allows investors a fair opportunity to act on it.
What makes insider trading particularly expansive is that liability does not depend on formal title. The law recognizes that duties of trust and confidence arise in a wide range of relationships. Employees, consultants, vendors, and even third parties who receive information under circumstances implying confidentiality may all be subject to the same restrictions. In ImmunityBio’s case, the individual was subject to company policies requiring pre-clearance of trades and prohibiting the use of confidential information, which reinforced her duty and ultimately supported the SEC’s findings.
The doctrine often applied in these situations, the “misappropriation theory”, focuses on whether a person improperly used information entrusted to them for personal gain. Under this framework, insider trading is less about corporate hierarchy and more about whether someone took advantage of information they were not entitled to use in the market.
What is particularly instructive in the SEC’s framing is its focus on state of mind; not in the sense of proving a calculated scheme, but in assessing whether the individual either knew, or was reckless in not knowing, that such individual’s conduct breached a duty to ImmunityBio. This distinction matters. Insider trading liability often turns on the recklessness conceptually rising to the requisite legal “intent”, which in this context reflects a conscious disregard of clear obligations rather than deliberate misconduct in a cinematic sense.
Here, the individual had already acknowledged ImmunityBio’s insider trading policies at the outset of employment, establishing both awareness and a defined duty. Against that backdrop, the decision to sell after learning of the FDA development, and, worse, to engage in yet more sales, reads less like an isolated lapse and more like a failure to adhere to obligations the individual had already accepted. From a practical perspective, repeated sales following receipt of such material FDA information, particularly in light of a specific acknowledgment of insider trading policies, strengthen the inference that the individual understood, or should have understood, the significance of her actions under the applicable facts and circumstances.
Another important, and often misunderstood, aspect of insider trading is that it does not require a profit. Avoiding a loss is treated the same as generating a gain. The economic benefit to the individual in the ImmunityBio proceeding was framed as losses avoided when the stock dropped following public disclosure of the FDA’s decision. This point is frequently overlooked outside legal circles but is central to how regulators evaluate trading conduct.
Equally notable is how these cases are proven. Contrary to popular belief, insider trading enforcement rarely hinges on dramatic “smoking gun” evidence. Instead, the SEC often builds its case through timing, context, and circumstantial evidence. In this matter, the proximity between the individual’s communications about the FDA development and her subsequent trades, combined with her knowledge of internal policies, formed a compelling narrative of misuse.
This is where the real-world risk diverges sharply from entertainment-driven perceptions. Insider trading does not typically involve elaborate schemes or coded messages. It more often arises from a moment of poor judgment, a decision to act on information that feels “informal,” “early,” or “not yet finalized,” but is nonetheless material and nonpublic. A text message, a late-night call, or an internal draft can be enough.
The consequences, however, are anything but minor. In addition to disgorgement of the economic benefit to the individual involved, the SEC imposed a civil penalty equal to the avoided losses, along with interest and a cease-and-desist order. Beyond regulatory penalties, such actions can expose individuals to reputational harm and potential follow-on litigation.
For businesses, the takeaway is structural. Insider trading risk is not confined to senior leadership and cannot be managed solely through high-level policies. Information flows through organizations in ways that are often informal and decentralized. As a result, compliance frameworks must account for all individuals who may come into contact with sensitive information, whether they are employees, contractors, or external partners.
For individuals, the lesson is more direct. Insider trading liability is not triggered by intent to “cheat the system” in a dramatic sense; it is triggered by using information that the market does not yet have. When in doubt, the safest course is not to trade.
Ultimately, insider trading law reflects a simple principle: markets function on fairness of access to information. The present matter is a reminder that breaches of that principle are often subtle, unremarkable in their execution, and entirely avoidable.